Origin | Single dose (50 μg/mL) inhibition at 24 h (%) | IC50of EAC-B at 48 h (μg/mL) | |||
---|---|---|---|---|---|
EAC-PE | EAC-B | EAC-E* | EAC-W** | ||
Gastric carcinoma (MGC-803) | 21.3 ± 1.3 | 87.0 ± 6.2 | 16.0 ± 2.0 | 12.1 ± 1.7 | 24.1 ± 3.7 |
Breast carcinoma (MDA-MB-435) | 19.9 ± 3.9 | 76.0 ± 0.4 | 15.4 ± 3.7 | 10.2 ± 3.0 | 26.0 ± 2.7 |
Myelogenous leukemia carcinoma (K-562) | 30.3 ± 0.3 | 73.9 ± 0.3 | 22.5 ± 3.8 | 17.3 ± 3.6 | 27.9 ± 7.8 |
Liver carcinoma (Bel7402) | 18.3 ± 1.1 | 65.9 ± 5.1 | 15.8 ± 3.6 | 3.6 ± 3.1 | 39.9 ± 6.1 |
Cervical carcinoma (Hela) | 11.6 ± 4.9 | 19.3 ± 1.3 | 13.5 ± 0.7 | 2.6 ± 1.5 | >50 |